Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: Evidence via computer simulations and implications for epilepsy therapy

Epilepsy Research

Volumn 87, Issue 2-3, 2009, Pages 260-267

  Reed, Ronald Charles ^a   Dutta, Sandeep ^a   Liu, Wei ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Delayed release; Divalproex; Extended release; Pharmacokinetics; Simulations; Valproic acid concentrations

Indexed keywords

VALPROATE SEMISODIUM;

ARTICLE; COMPUTER SIMULATION; DELAYED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; ENTERIC COATED TABLET; EPILEPSY; EVIDENCE BASED PRACTICE; EXTENDED RELEASE FORMULATION; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL;

ANTICONVULSANTS; AREA UNDER CURVE; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; HUMANS; MODELS, BIOLOGICAL; TIME FACTORS; VALPROIC ACID;

EID: 70449634948     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.09.015     Document Type: Article

References (73)

1. Anderson G.D. Anticonvulsant agents. In: Schoenwald R.D. (Ed). Pharmacokinetics in Drug Discovery and Development (2002), CRC Press, Boca Raton, FL, USA 231-264 (Chapter 11)
2. Anon., 2008. National Coordinating Council for medication error reporting and prevention, promoting the safe use of suffixes in prescription drug names. Available at: www.nccmerp.org/council/council2008-08-01.html (accessed 08.11.09).
3. Anon., 2009. Pennsylvania Patient Safety Authority. Drug name suffix confusion is a common source of errors. Available at: www.psa.state.pa.us/psa/lib/psa/advisories/v1ndecember2004/dec2004vol14_article_k_drug_name_confusion.pdf (accessed 08.11.09).
4. Arroyo S. Valproate. In: Shorvon S., Perucca E., Fish D., and Dodson E. (Eds). The Treatment of Epilepsy. 2nd edition (2004), Blackwell Science, MA, USA 528-539 (chapter 46)
5. Becker W.J. Evidence based migraine prophylactic drug therapy. Can. J. Neurol. Sci. 26 Suppl. 3 (1999) S27-S32
6. Beydoun A., Sackellares J.C., Shu V., and the Depakote monotherapy for partial seizures study group. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology 48 (1997) 182-188
7. Blanco-Serrano B., Otero M.J., Santos-Buelga D., et al. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm. Drug Dispos. 20 (1999) 233-240
8. Boggs J., and Reed R.C. Clinical intoxication and breakthrough seizures resulting from substitution of enteric-coated divalproex for once-daily extended release divalproex. Epilepsia 47 Suppl 4 (2006) 188 Poster #2.202
9. Bourgeois B.F.D. Valproic acid: Clinical Efficacy and Use in Epilepsy. In: Levy R.H., et al. (Ed). Antiepileptic Drugs (2002), Raven Press, New York 808-817 (chapter 86)
10. Bowdle T.A., Patel I.H., Levy R.H., et al. Valproic acid dosage and plasma protein binding and clearance. Clin. Pharmacol. Ther. 28 4 (1980) 486-492
11. Bowden C.L., Brugger A.M., Swann A.C., et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania, The Depakote Mania Study Group. J. Am. Med. Assoc. 271 12 (1994) 918-924
12. Bowden C.L., Swann A.C., Calabrese J.R., et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the treatment of acute mania. J. Clin. Psychiatry 67 10 (2006) 1501-1510
13. Brodie M.J., and French J.A. Management of epilepsy in adolescents and adults. Lancet 356 (2000) 323-329
14. Browne T.R., and Holmes G.L. Epilepsy. N. Engl. J. Med. 344 15 (2001) 1145-1151
15. Bruni J., Wilder B.J., Willmore L.J., et al. Clinical efficacy of valproic acid in relation to plasma levels. Le Journal Canadien des Sciences Neurologiques 5 4 (1978) 385-387
16. Chadwick D.W. Concentration-effect relationships of valproic acid. Clin. Pharmacokinet. 10 (1985) 155-163
17. Cloyd J.C., Fischer J.H., Kriel R.L., et al. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin. Pharmacol. Ther. 53 (1993) 22-29
18. Cloyd J.C., Dutta S., Cao G., et al. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 53 (2003) 19-27
19. Cohen M.R. ISMP medication error report analysis-Depakote ER: easy to confuse with Depakote (delayed-release). Hosp. Pharm. 36 4 (2001) 382-383. http://www.ismp.org/Newsletters/acutecare/articles/20010207-1.asp http://www.ismp.org/Newsletters/acutecare/articles/20010207-1.asp (accessed 08.11.09)
20. Covanis A., and Jeavons P.M. Once-daily sodium valproate in the treatment of epilepsy. Dev. Med. Child Neurol. 22 (1980) 202-204
21. Covanis A., Gupta A.K., and Jeavons P.M. Sodium valproate: monotherapy and polytherapy. Epilepsia 23 (1982) 693-720
22. ®, (Divalproex Sodium Enteric-coated, Delayed-release Tablets) Product Information, 2005. Abbott Laboratories, North Chicago, IL, USA.
23. ®ER, (Divalproex Sodium Extended-Release Tablets) Product Information, 2006. Abbott Laboratories, North Chicago, IL, USA.
24. Doughty J., Baker G.A., Jacoby A., and Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav. 4 6 (2003) 710-716
25. Dulac O., and Alvarez J.C. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations, after once- or twice-daily administration. Pharmacotherapy 25 1 (2005) 35-41
26. Dutta S., Zhang Y., Selness D.S., et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 49 1 (2002) 1-10
27. Dutta S., and Reed R.C. Divalproex to divalproex extended-release conversion. Clin. Drug Invest. 24 9 (2004) 495-508
28. Dutta S., and Reed R.C. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res. 73 (2007) 275-283
29. Dutta S., Reed R.C., and Cavanaugh J.H. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. Am. J. Health-Syst. Pharm. 61 21 (2004) 2280-2283
30. Dutta S., Reed R.C., and Cavanaugh J.H. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J. Clin. Pharmacol. 44 7 (2004) 737-742
31. Dutta S., and Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm. Drug Dispos. 25 8 (2004) 345-352
32. Dutta S., Zhang Y., Conway J.M., et al. Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr. Neurol. 30 5 (2004) 330-337
33. Dutta S., Reed R.C., and O'Dea R.F. Comparative absorption profiles of divalproex sodium delayed-release vs. extended-release tablets: clinical implications. Ann. Pharmacother. 40 (2006) 619-625
34. Dutta S., and Reed R.C. Effect of missed and delayed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. J. Clin. Pharm. Ther. 31 4 (2006) 321-329
35. Felix S., Sproule B.A., Hardy B.G., et al. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. J. Clin. Psychopharmacol. 23 (2003) 471-478
36. Freitag F., Collins S.D., Carlson H.A., et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58 (2002) 1652-1659
37. Genton P. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate. Acta Neurol. Scand. 112 Suppl. 182 (2005) 26-32
38. Gidal B.E., Pitterle M.E., Spencer N.W., et al. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J. Clin. Pharm. Ther. 20 (1995) 215-219
39. Gjerloff I., Arentsen J., Jorgen A., et al. Monodose versus three daily doses of sodium valproate: a controlled trial. Acta Neurol. Scand. 69 (1984) 120-124
40. Gomez-Bellver M.J., Garcia-Sanchez M.J., Alonso-Gonzalez A.C., et al. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J. Clin. Pharm. Ther. 18 (1993) 191-197
41. Gram L., Flachs H., Wurtz-Jorgensen A., et al. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 20 3 (1979) 303-311
42. Grissinger M. Depakote ER formulation warrants safety reminder. Pharm. Ther. 26 (2001) 352 (the same case was also reported in Reactions Weekly, 2001;877, 12)
43. Henriksen O., and Johannssen S.I. Clinical and pharmacokinetic observations on sodium valproate-a 5-year follow-up study in 100 children with epilepsy. Acta Neurol. Scand. 65 (1982) 504-523
44. Holquist C., and Fava R. FDA safety page: delayed-release vs. extended-release Rxs. Drug Top. July (2007) 56. http://drugtopics.modernmedicine.com/drugtopics/Top+News/FDA-safety-page-Delayed-release-vs-extended-releas/ArticleStandard/Article/detail/442606 (also available at: http://drugtopics.modernmedicine.com/drugtopics/Top+News/FDA-safety-page-Delayed-release-vs-extended-releas/ArticleStandard/Article/detail/442606 (accessed 08.11.09)
45. Ieiri I., Morioka T., Ichimiya T., et al. Pharmacokinetic study of valproic acid sustained-release preparation in patients undergoing brain surgery. Ther. Drug Monit. 17 (1995) 6-11
46. Lesar T.S. Prescribing errors involving medication dosage forms. J. Gen. Intern. Med. 17 (2002) 587-597
47. Levy R.H., Shen D.D., Abbott F.S., et al. Valproic acid- Chemistry, Biotransformation and Pharmacokinetics. In: Levy R.H., et al. (Ed). Antiepileptic Drugs. 5th edition (2002), Raven Press, New York 780-800 (chapter 84)
48. Lundberg B., Nergardh A., and Boreus L.O. Plasma concentrations of valproate during maintenance therapy in epilepsy children. J. Neurol. 228 2 (1982) 133-141
49. Mathew N.T., Saper J.R., Silberstein S.D., et al. Migraine prophylaxis with divalproex. Arch. Neurol. 52 3 (1995) 281-286
50. Ohtsuka Y., Amano R., Mizukawa M., et al. Treatment of intractable childhood epilepsy with high-dose valproate. Epilepsia 33 1 (1992) 158-164
51. Park H.M., Kang S.S., Lee Y.B., et al. Population pharmacokinetics of intravenous valproic acid in Korean patients. J. Clin. Pharm. Ther. 27 (2002) 419-435
52. Pelzl G., and Mamoli B. Single daily dose of valproic acid: a pharmacodynamic and clinical study. Wien. Klin. Wochenschr. 104 10 (1992) 286-289
53. Pellock J.M., Smith M.C., Cloyd J.C., et al. Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav. 5 3 (2004) 301-307
54. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants. Clin. Pharmacokinet. 38 3 (2000) 191-204
55. Perucca E., Albani F., Capovilla G., et al. Recommendations of the Italian League Against Epilepsy Working Group on generic products of antiepileptic drugs. Epilepsia 47 Suppl. 5 (2006) 16-20
56. Pope H.G., McElroy S.L., Keck P.E., et al. Valproate in the treatment of acute mania-a placebo-controlled study. Arch. Gen. Psychiatry 48 1 (1991) 62-68
57. Reed R.C., and Dutta S. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium. Am. J. Health-Syst. Pharm. 61 21 (2004) 2284-2289
58. Reed, R.C., Meinhold, J., Dutta, S., Liu, W., Qiu, Y., in press. What do the suffixes - XR, ER, Chrono, Chronosphere - really mean as it pertains to modified-release antiepileptic drugs?. J. Clin. Pharm. Ther.
59. Rinnerthaler M., Luef G., Mueller J., et al. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. Epilepsia 46 2 (2005) 320-323
60. Roberts D., Easter D., and O'Bryan-Tear G. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. Biopharm. Drug Dispos. 17 (1996) 175-182
61. Rowan A.J., Binnie C.D., Beer-Pawlikowski N.K.B., et al. Serial twenty-four hour serum level monitoring in the study of sodium valproate in the treatment of epilepsy. In: Parsonage M.J., and Caldwell A.D.S. (Eds). The Place of Sodium Valproate in the Treatment of Epilepsy, Royal Society of Medicine International Congress and Symposium Series, No. 30 (1980), Academic Press Inc., London 115-122
62. Schobben F., Van der Kleijn E., and Gabreels F.J.M. Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur. J. Clin. Pharmacol. 8 (1975) 97-105
63. Smith M.C., Centorrino F., Welge J.A., et al. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav. 5 (2004) 746-751
64. Sommerville K.W., Dutta S., Biton V., et al. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clin. Drug Invest. 23 10 (2003) 661-670
65. Stefan H., Burr W., Fichsel H., et al. Intensive follow-up monitoring in patients with once daily evening administration of sodium valproate. Epilepsia 25 (1984) 152-160
66. Thibault M., Blume W.T., Saint-Hilaire J.M., et al. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res. 50 (2002) 243-249
67. Turnbull D.M., Rawlins M.D., Weightman D., and Chadwick D.W. Plasma concentrations of sodium valproate: their clinical value. Ann. Neurol. 14 (1983) 38-42
68. Van Duijn H., Meijer J.W.A., and Segers J.P. To what extent is drug entry into brain dependent on the way of administration? Some dipropylacetic acid experiments on cats. In: Gardner-Thorpe C., Janz D., Meinardi H., and Pippenger C.E. (Eds). Antiepileptic Drug Monitoring (1977), Pitman Medical Publishing, England
69. Van Raay L., Morris M., Reed R.C., Hogan R.E., O'Brien T.J., and Dedeurwaerdere S.M. Does intermittent administration of valproate result in better seizure suppression compared to continuous administration in two rat models of epilepsy?. Epilepsia 49 Suppl. 7 (2008) 108 Abstract/poster #1.246
70. Villarreal H.J., Wilder B.J., Willmore L.J., et al. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 28 (1978) 886-891
71. Wieser H.G. Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valproamide. Epilepsy Res. 9 (1991) 154-159
72. Willmore L.J., Shu V., Wallin B., and the M88-194 Study Group. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. Neurology 46 (1996) 49-53
73. Yukawa E., To H., Ohdo S., et al. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interactions and patient characteristics. J. Clin. Pharmacol. 37 (1997) 1160-1167